Celyad Oncology SA (EBR:CYAD)

Belgium flag Belgium · Delayed Price · Currency is EUR
0.318
+0.016 (5.30%)
Apr 28, 2026, 5:27 PM CET
-33.89%
Market Cap 14.23M
Revenue (ttm) 21.00K
Net Income (ttm) 830.00K
Shares Out 44.76M
EPS (ttm) 0.02
PE Ratio 17.67
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 15,177
Average Volume 15,145
Open 0.315
Previous Close 0.302
Day's Range 0.305 - 0.319
52-Week Range 0.160 - 0.650
Beta 1.22
RSI 49.71
Earnings Date Apr 2, 2026

About Celyad Oncology

Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the T-cell receptor (TCR) without the need for gene editing; NKG2D-based CAR T-cells and multi-specific CAR T-cell platform; and B7-H6 targeting CAR T-... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 5
Stock Exchange Euronext Brussels
Ticker Symbol CYAD
Full Company Profile

Financial Performance

Financial Statements